Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report

Investing.com — Rhythm Pharmaceuticals (NASDAQ) shares surged 28% on Wednesday after The Wall Street Journal reported that AstraZeneca (NASDAQ) had made a $10 billion acquisition offer for the biotech company.

Still guessing which stocks will beat the market? Our AI portfolio updates monthly and is outperforming the S&P 500 by 118%. See this month’s list »

According to the report, the U.K.-based drugmaker offered $124 per share for Rhythm last month. Rhythm shares closed at $110.68, up from around $95 earlier in the session, giving the company a market capitalization of approximately $7.7 billion at the close, compared with roughly $6.6 billion earlier in the day.

Unsure what to buy ahead of earnings? Our AI’s recent pre-earnings calls delivered gains of +77% to +118% after results dropped. See this month’s earnings picks »

A potential acquisition would expand AstraZeneca’s portfolio of rare disease treatments. Rhythm specializes in therapies for rare metabolic disorders, including severe obesity.

AstraZeneca had previously expressed interest in acquiring Rhythm, according to people familiar with the matter cited by the Journal.

Original Article

Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report

Dow posts best day in 19 months as investors cheer removal of midterms uncertainty

Qualcomm falls 3% as handset revenue misses estimates, costs rise